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OBJECTIVE: Marfan syndrome (MFS) is caused by mutations in FBN1 (fibrillin-1), an extracellular matrix (ECM) component, which is 
modified post-translationally by glycosylation. This study aimed to characterize the glycoproteome of the aortic ECM from patients 
with MFS and relate it to aortopathy.
APPROACH AND RESULTS: ECM extracts of aneurysmal ascending aortic tissue from patients with and without MFS were enriched 
for glycopeptides. Direct N-glycopeptide analysis by mass spectrometry identified 141 glycoforms from 47 glycosites within 35 
glycoproteins in the human aortic ECM. Notably, MFAP4 (microfibril-associated glycoprotein 4) showed increased and more diverse 
N-glycosylation in patients with MFS compared with control patients. MFAP4 mRNA levels were markedly higher in MFS aortic 
tissue. MFAP4 protein levels were also increased at the predilection (convexity) site for ascending aorta aneurysm in bicuspid aortic 
valve patients, preceding aortic dilatation. In human aortic smooth muscle cells, MFAP4 mRNA expression was induced by TGF 
(transforming growth factor)-β1 whereas siRNA knockdown of MFAP4 decreased FBN1 but increased elastin expression. These 
ECM changes were accompanied by differential gene expression and protein abundance of proteases from ADAMTS (a disintegrin 
and metalloproteinase with thrombospondin motifs) family and their proteoglycan substrates, respectively. Finally, high plasma 
MFAP4 concentrations in patients with MFS were associated with a lower thoracic descending aorta distensibility and greater 
incidence of type B aortic dissection during 68 months follow-up.
CONCLUSIONS: Our glycoproteomics analysis revealed that MFAP4 glycosylation is enhanced, as well as its expression during the 
advanced, aneurysmal stages of MFS compared with control aneurysms from patients without MFS.
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Marfan syndrome (MFS) is an autosomal genetic disease, with at least 90% of patients exhibiting mutations within the gene encoding for the extra-
cellular matrix (ECM) glycoprotein fibrillin-1 (FBN1).1 In 
the aorta, FBN1 (fibrillin-1) is linked to vascular smooth 
muscle cells (SMCs) by integrins as well as within elastin 
microfibrils within the ECM.2,3 FBN1 mutations are either 
haploinsufficient or dominant negative, which seems to 
influence the MFS phenotype.1 In addition to aneurysms, 
aortic dissections constitute a significant number of 
life-threatening events in patients with MFS.4 While 
dissections of the ascending aorta (type A) are largely 
prevented by aggressive prophylactic aortic surgery, the 
dissections of the thoracic descending aorta (type B) 
usually present asymptomatically later in life, at an aortic 
diameter far below the 4.5 cm cutoff value for surgery.5
One proposed mechanism involved in MFS aortop-
athy is the function of FBN1 as a regulator of TGF-β 
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(transforming growth factor β) bioavailability, whereby 
defective FBN1 production leads to heightened TGF-β 
signaling and eventual aortic dilatation and aneurysm 
in mice. However, clinical studies showed that losartan 
had no superior therapeutic effect, when compared with 
or used as an additive to standard β-blocker adminis-
tration in undifferentiated MFS cohorts.6–8 Thus, a bet-
ter understanding of the downstream consequences of 
defective FBN1 on ECM remodeling that leads to the 
structural failure of the vessel wall in MFS is required. 
ECM remodeling may involve the canonical function of 
FBN1 in elastic fiber synthesis and cross-linking9 as well 
as post-translational modifications (PTMs) that regulate 
the function of ECM proteins.
Given that MFS results in high mortality because of 
aortopathy, a strong focus has been on elastin and col-
lagen, the 2 predominant ECM components governing 
the structural integrity of the vascular wall.3 MFS aortas 
display not only abnormal organization and metabolism 
of collagen and elastin fibers with an abnormal appear-
ance of microfibrils10 but also a significant component of 
ECM degradation,11,12 as confirmed using 3-dimensional 
confocal imaging and atomic force microscopy.13
Interestingly, mutations in FBN1 causing MFS include 
those affecting PTMs of the protein, for example, the 
generation of an extra N-glycosylation site on FBN1.14 
Aberrant glycosylation of proteins alters their folding, 
solubility, binding, and degradation.15 Interestingly, a large 
proportion of ECM proteins contain glycosylation sites, 
and the glycosylation profiles of FBN1 and other ECM 
constituents could, therefore, be relevant to the pathol-
ogy of MFS. Given the technical challenges associated 
with the study of glycosylation, this key PTM has long 
been neglected. Only recent advances in glycopro-
teomics have made it feasible to directly analyze glyco-
peptides using mass spectrometry (MS).16,17 Over recent 
years, we have developed extraction methods to enrich 
for ECM proteins in cardiovascular tissues18 that are also 
amenable for direct analysis of glycosylation by MS.19
In the present study, we have applied this MS method 
to analyze the ECM glycoproteome in thoracic aortic 
aneurysms from patients with and without MFS. For the 
first time, we demonstrate aberrant glycosylation of the 
FBN1-interacting MFAP4 (microfibril-associated glyco-
protein 4) in MFS and provide evidence for its poten-
tial application as a novel plasma biomarker to identify 
patients with MFS at risk for type B aortic dissection.
MATERIALS AND METHODS
The data that support the findings of this study are available 
from the corresponding author upon reasonable request.
Sample Collection From Patients With MFS
For glycoproteomic analysis, aortic aneurysmal tissue was col-
lected during surgery from 11 patients with MFS and 6 patients 
without MFS who had undergone aortic root and ascending 
aorta replacement (Table I in the online-only Data Supplement). 
Of the 6 patients without MFS, 3 had a known mutation, namely 
for TGF-β receptor type-1 (TGFBR1), elastin (ELN), and aortic 
smooth muscle actin (ACTA2). No mutation was found for the 
other 3 patients based on current mutation screening. A local 
Nonstandard Abbreviations and Acronyms
ADAMTS   a disintegrin and metalloproteinase 
with thrombospondin motifs
ALKi   activin receptor-like kinase 4,5,7 
inhibitor
BAV  bicuspid aortic valve
CSPG2  proteoglycans versican
ECM  extracellular matrix
ETD  electron transfer dissociation
FBN1  fibrillin-1
GuHCl  guanidine hydrochloride
HCD   higher-energy collisional 
dissociation
iPSC  induced pluripotent stem cell
LC-MS/MS  liquid chromatography-tandem 
mass spectrometry
LTBP   Latent-transforming growth factor 
β-binding protein
MAGPs  microfibril-associated glycoproteins
MFAP4  microfibril-associated glycoprotein 4
MFS  Marfan syndrome
PGCA  proteoglycans aggrecan
PTMs  post-translational modifications
qPCR   quantitative polymerase chain 
reaction
SMCs  smooth muscle cells
TAV  tricuspid aortic valve
TGF-β  transforming growth factor β
Highlights
• Glycoproteomics analysis revealed enhanced 
MFAP4 (microfibril-associated glycoprotein 4) levels 
in the extracellular matrix of ascending aorta from 
patients with Marfan syndrome compared to without 
Marfan syndrome aneurysm patients.
• Silencing MFAP4 expression in aortic smooth mus-
cle cells had a profound impact on the expression 
of elastin and fibrillin-1, as well as ADAMTS (a dis-
integrin and metalloproteinase with thrombospondin 
motifs) proteases.
• High levels of plasma MFAP4 might be associ-
ated with reduced distensibility of the descending 
aorta and predict the probability of a type B aortic 
dissection.
D
ow
nloaded from
 http://ahajournals.org by on July 31, 2019
ORIGINAL RESEARCH - VB
Yin et al Glycoproteomics of Marfan Syndrome
Arterioscler Thromb Vasc Biol. 2019;39:00–00. DOI: 10.1161/ATVBAHA.118.312175 September 2019 3
Research Ethics Committee gave approval for the use of these 
samples when used anonymously (Ref number W16_037 no. 
16.052). For plasma analysis, the same patients with MFS, who 
were from a subset of the COMPARE trial (NTR1423)20 and 
included in a study on plasma TGF-β1 in aortic disease,21,22 
were used to measure plasma MFAP4 concentration. Inclusion 
criteria of the COMPARE trial were the diagnosis of MFS was 
according to the Ghent criteria23 relevant at the time and an 
age of >18 years. The exclusion criteria were angiotensin-
converting enzyme inhibitor usage and previous replacement 
of more than one part of the aorta. However, in this substudy, 
all patients were included irrespective of the medication they 
used, and patients with prior aortic surgery were also allowed.20 
At the time of inclusion, plasma samples (n=96) from patients 
with MFS were obtained, and aortic root diameters were mea-
sured. Written consent was obtained from all patients included 
in this study.
ECM Extraction From Aortic Tissue
Human aortic tissues were diced into small pieces and sub-
jected to our 3-step extraction.18 First, the tissues were incu-
bated in a sodium chloride (NaCl, 10X volume: weight, ie, 10 
µL per 1 mg) buffer (0.5 mol/L NaCl, 10 mmol/L Tris, pH 
7.5, 25 mmol/L EDTA, supplemented with Protease Inhibitor 
Cocktail from Sigma, Catalog no. P8340), with slow agitation 
for 4 hours. The NaCl fraction was transferred into a new tube 
and kept at −80°C for later use. Subsequently, the tissues 
were decellularized by incubation in a sodium dodecyl sulphate 
(SDS, 10X volume: weight) buffer (0.08% SDS, 25 mmol/L 
EDTA, supplemented with Proteinase Inhibitor Cocktail) with 
slow agitation for 4 hours. The SDS fraction was transferred 
into a new tube and kept at −80°C for later use. Finally, the 
samples were incubated in a guanidine hydrochloride (GuHCl, 
5X volume: weight) buffer (4 mol/L GuHCl, 50 mmol/L sodium 
acetate, pH 5.8, 25 mmol/L EDTA supplemented with Protease 
Inhibitor Cocktail) with vigorous agitation for 48 hours. The 
GuHCl fraction was recovered and stored at −80°C for later 
use. Protein concentrations of NaCl and GuHCl fractions were 
estimated using Nanodrop spectrophotometer (ND-1000, 
Thermo Fisher Scientific) at 280 nm.
Glycopeptide Enrichment
One hundred micrograms of protein from the GuHCl fraction 
per sample were precipitated using 100% ethanol overnight at 
−20°C. After centrifugation at 14000g for 30 minutes at 4°C, 
the pellets were briefly dried using a SpeedVac (Thermo Fisher 
Scientific, Savant SPD131DDA) and resuspended in 0.1% 
SDS, 50 mmol/L Tris-HCl, pH 8.8. After reduction with 10 
mmol/L dithiothreitol followed by incubation at 37°C for 1 hour, 
240 rpm, the samples were cooled down to room temperature 
before being alkylated by 50 mmol/L iodoacetamide followed 
by incubation in the dark for 1 hour. Prechilled (−20°C) acetone 
(8× volume) was used to precipitate the samples overnight at 
−20°C. Samples were centrifuged at 14000g for 30 minutes 
at 4°C and the supernatant subsequently discarded. Protein 
pellets were briefly dried using SpeedVac and resuspended in 
100 µL of 0.1 mol/L triethylammonium bicarbonate (pH=8.2) 
then digested with 2 µg of trypsin (MS Grade, TPCK-treated 
to eliminate chymotryptic activity, Thermo Fisher Scientific) 
at 37°C overnight. Peptides were labeled with Tandem Mass 
Tag zero reagent (TMT0, Thermo Scientific Scientific) follow-
ing the manufacturer’s instructions. Labeled peptides were fur-
ther enriched for glycopeptides using zwitterionic hydrophilic 
interaction liquid chromatography resin (ZIC-HILIC, Merck).17 
Glycopeptide fractions were dried using SpeedVac and resus-
pended in 5% acetonitrile, 0.1% trifluoroacetic acid in H2O.
Glycoproteomics Analysis
The glycopeptide enriched fraction was separated using the 
EASY-nLC liquid chromatography (LC) system (Thermo Fisher 
Scientific) with a Magic C18 spray tip 15 cm×75 µm column 
(Bruker-Michrom, Auburn, CA). Peptides were eluted using 
4% to 30% acetonitrile, 0.1% formic acid within 1 hour at a 
flow rate of 300 nL/min and directly analyzed with an Orbitrap 
Elite hybrid MS (Thermo Fisher Scientific) with electron trans-
fer dissociation (ETD). Two MS/MS methods were used. For 
alternating higher-energy collisional dissociation (HCD) and 
ETD MS/MS (HCD-alt-ETD) method, the top 10 ions were 
analyzed via HCD and ETD. For HCD product-dependent 
ETD (HCD-pd-ETD) method, the top 10 ions were analyzed 
via HCD, and product-dependent ETD acquisition was trig-
gered by product (oxonium) ions (m/z 163.0812 for Hex; m/z 
204.0864 for HexNAc; m/z 138.0554 for HexNAc fragment 
ion). Glycopeptides were identified using Byonic software (ver-
sion 2.9.30, Proteome Metrics).17 Identified glycoforms were 
quantified using Pinnacle software (version 1.0.65.0, Optys 
Tech Corporation, Boston, MA). The precursor peak area was 
used and normalized to the total ion current. The 2 RAW files 
from the same sample using different fragmentation methods 
were used as technical replicates for quantitation.
Proteomics Analysis of Aortic Samples From 
Patients With Bicuspid Aortic Valve
Aortic samples from bicuspid aortic valve (BAV) patients and 
tricuspid aortic valve (TAV) patients were collected during aortic 
surgery at St George’s Hospital. All procedures were approved 
by the Regional Ethics Committee Board (London, REC num-
ber 08/H0803/257). The diagnosis of BAV was confirmed by 
direct visualization of the valve phenotype. For each patient, 2 
aortic specimens were collected, one from the concave area 
and one from the convex area of the ascending aorta and 
immediately snap-frozen at −80°C for proteomic analysis 
(Table II in the online-only Data Supplement). The samples 
were anonymized directly after surgery and before the experi-
mental procedure and analysis.
ECM proteins were extracted using the same method as 
described above. Twenty micrograms of proteins from GuHCl 
fractions were precipitated in 100% ethanol, and the pel-
lets were resuspended in deglycosylation buffer (0.2 mol/L 
Tris, 0.2 mol/L sodium acetate, 0.1 mol/L EDTA, 50 mmol/L 
sodium phosphate, pH 6.8). The following deglycosylation 
enzymes were used: endo-α-N-acetylgalactosaminidase, 
β1,4-galactosidase, β-N-acetylglucosaminidase, α-2-3,6,8,9-
Neuraminidase (all from Merck-Millipore Glycoprotein 
Deglycosylation Kit, Catalog no. 362280), Chondroitinase 
ABC (Sigma-Aldrich, C3667), Heparinase II (Sigma-Aldrich, 
H6512), and Endo-β1,4-galactosidase (Sigma-Aldrich, 
G6920). Samples were incubated for 1 hour at 25°C, followed 
by 24 hours at 37°C in agitation then dried using SpeedVac. 
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Subsequently, samples were reconstituted in O18 water con-
taining N-Glycosidase F (PNGase F, from the Merck-Millipore 
Glycoprotein Deglycosylation Kit, Cat No. 362280) and incu-
bated at 37°C with agitation for 24 hours.
After deglycosylation, proteins were denatured using 6 
mol/L urea, 2 mol/L thiourea, reduced with 10 mmol/L dithio-
threitol, and alkylated with 50 mmol/L iodoacetamide. Proteins 
were precipitated by prechilled acetone overnight, resuspended 
in 0.1 mol/L triethylammonium bicarbonate and digested 
with 0.4 µg trypsin overnight. The digestion was stopped by 
1% trifluoroacetic acid. Peptide samples were purified using 
a 96-well C18 spin plate (Harvard Apparatus). The eluates 
were frozen at −80°C for 2 hours before being immediately 
lyophilized (Christ Alpha 1–2 LD plus) at −55°C overnight. The 
peptides of BAV samples were reconstituted with 2% ace-
tonitrile, 0.05% trifluoroacetic acid in H2O, and separated on 
a nanoflow LC system (UltiMate 3000 RSLCnano). Samples 
were injected onto a trap column (Acclaim PepMap100 C18 
Trap, 5 mm×300 µm) at a flow rate of 25 µL/min for 3 minutes, 
using 2% acetonitrile, 0.1% formic acid in H2O. The following 
LC gradient was then used to separate the peptides at 300 nL/
min: 0 to 10 minutes, 2% to 10% B; 10 to 200 minutes, 10% 
to 30% B; 200 to 210 minutes, 30% to 40% B; 210 to 220 
minutes, 99% B, 220 to 240 minutes 2% B, where A=0.1% 
formic acid in H2O, B=80% acetonitrile, 0.1% formic acid in 
H2O. The reverse phase column (Acclaim PepMap100 C18, 
50 cm×75 µm) was set at 40°C and coupled to a nanospray 
source (Picoview, New Objective, US). Spectra were collected 
from a Thermo Q Exactive HF Mass Spectrometer (QE HF MS, 
Thermo Fisher Scientific) using full MS mode over the mass-
to-charge (m/z) range 350 to 1600. Data-dependent MS/MS 
scan was performed on the most abundant 15 ions in each full 
MS scan with dynamic exclusion enabled.
Proteome Discoverer (version 2.2.0.388, Thermo Fisher 
Scientific) was used to search raw data files against the human 
database (UniProtKB/Swiss-Prot version 2018_05, 20349 
protein entries) using Mascot (version 2.6.0, Matrix Science). 
The mass tolerance was set at 10 ppm for precursor ions and 
20 mmu for fragment ions. Trypsin was used as the enzyme 
with 2 missed cleavages being allowed. Carbamidomethylation 
of cysteine was chosen as a fixed modification; oxidation of 
methionine, lysine and proline, and deamidation of aspara-
gine in the presence of O18 water were chosen as variable 
modifications. Scaffold (version 4.8.7, Proteome Software Inc, 
Portland, OR) was used to validate MS/MS-based peptide and 
protein identifications with the following filters: a peptide prob-
ability of >95.0%, a protein probability of >99.0%, and at least 
2 independent peptides per protein. The normalized total ion 
current was used for quantification.24
Selected proteins were quantified in the BAV samples, as 
well as TAV samples, using multiple reaction monitoring on an 
UltiMate 3000 RSLCnano system with the same setup, cou-
pled to a triple quadrupole MS (TSQ Vantage, Thermo Fisher 
Scientific). The TSQ Vantage was set in positive ion mode with 
ion transfer capillary temperature at 275°C and spray voltage 
at 3200 V. Both Q1 and Q3 were set at unit mass resolution 
(0.7Th FWHM), and argon was used as the collision gas at 1.0 
mTorr. For the scheduled multiple reaction monitoring method, 
a retention time window of 8 minutes and a cycle time of 1.43 
seconds were used. Skyline software (version 3.1, MacCoss 
Lab Software) was used to generate the transition list with 
predicted collision energies as well as optimized transitions 
(Table XI in the online-only Data Supplement). Multiple reac-
tion monitoring data were analyzed by Skyline. All peaks were 
reviewed and integrated manually. Total fragment peak areas 
were used for quantification.
Immunoblotting
Proteins from the GuHCl and NaCl fractions were precipi-
tated in 100% ethanol or acetone, respectively, overnight at 
−20°C and deglycosylated as described in BAV sample prepa-
ration method, except that PNGase F was added in parallel 
to the other enzymes, and the incubation was performed in 
one step, for 48 hours at 37°C. Deglycosylated proteins were 
denatured with reducing Laemmli sample buffer at 97°C for 5 
minutes, separated by SDS-PAGE using 4% to 12% Bis-Tris 
gels (Invitrogen), transferred to nitrocellulose membranes (GE 
Healthcare), and subjected to immunoblotting following stan-
dard protocols. The following primary antibodies were used: 
MFAP4 (Abcam, ab169757), aggrecan neoepitope (Thermo 
Fisher Scientific, PA1-1746), versican neoepitope (Abcam, 
ab19345), and TGF-β1 (Abcam, ab179695) (please see the 
Major Resources Table in the online-only Data Supplement). 
Primary antibodies were detected by anti-rabbit light-chain 
specific secondary antibodies linked to horseradish peroxi-
dase (Jackson ImmunoResearch Europe Ltd, 211-032-171). 
Protein bands were detected by enhanced chemiluminescence 
(GE Healthcare) on an x-ray film. The film was scanned and 
quantified using Image Quant TL (version 8.1, GE Healthcare).
SMC Culture With TGF-β1
Primary human aortic SMCs (PromoCell, C-12533, 3 dif-
ferent donors, see Major Resources Table in the online-only 
Data Supplement) were cultured in DMEM with 2 mmol/L 
L-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin, 
and 20% fetal bovine serum. Murine aortic SMCs were cultured 
from wild-type C57Bl6/J aortas after enzymatic digestion as 
described previously.25 Murine aortic SMCs were cultured 
similarly, yet with DMEM/F12. Cell experiments were initiated 
with a subconfluent SMC layer at passage 6 to 10. The SMC 
was preincubated with serum-free medium for 24 hours, fol-
lowed by a 24-hour incubation with 10 ng/mL recombinant 
TGF-β1 (R&D, Catalog No. 240-B-002) with or without 10 
µmol/L of the ALKi (activin receptor-like kinase 4,5,7 inhibi-
tor) SB 431542 (R&D, Catalog No. 1614) to block TGF-β type 
I receptors. Independent culture experiments were performed 
and normalized to the controls (no TGF-β1 and no ALKi) for 
comparison of fold change after TGF-β1 or simultaneous TGF-
β1 and ALKi treatment.
Silencing of MFAP4 in Human Aortic SMCs
Human aortic SMCs (PromoCell, C-12533, 3 different donors) 
were cultured on 6-well plates (1.5×105 cells/well) using SMC 
Growth Medium 2 (PromoCell C-22062) until 70% conflu-
ent. MFAP4 siRNA (50 nmol/L, Life Technologies, Catalog no. 
AM16708, Assay ID: 11386) and control siRNA (50 nmol/L, 
Life Technologies, Catalog no. AM4613) were transfected by 
using lipofectamine in different passages of different donors (2 
for donor 1, 7 for donor 2, and 5 for donor 3) for 6 hours then in 
M199 with 100 U/mL penicillin, 100 µg/mL streptomycin, and 
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2.5% fetal bovine serum overnight. After replaced with com-
plete medium (M199 with 100 U/mL penicillin, 100 µg/mL 
streptomycin, and 20% fetal bovine serum) and cultured for 48 
hours, the cells were washed using M199 3 times, and further 
cultured in M199 for 24 hours. The cells were harvested for 
RNA extraction as detailed below. In total, 14 individual experi-
ments using 3 different cell lines were performed for each con-
dition. The experiment was repeated with a different MFAP4 
siRNA at a lower concentration (25 nmol/L, Life Technologies, 
Catalog no. 4392420, Assay ID: s8716).
Correction of FBN1 in MFS-Derived Induced 
Pluripotent Stem Cell-SMCs
Patients with MFS fibroblasts (GM21943, Coriell Institute) 
were reprogrammed into human induced pluripotent stem cells 
(iPSCs), and the mutation was corrected by CRISPR-Cas9 
to generate an isogenic control.26 Control and Marfan iPSCs 
were grown on Vitronectin XF (STEMCELL Technologies) and 
maintained in mTeSR E8 media (STEMCELL Technologies). 
They were then differentiated into neural crest SMCs using 
the methods described previously.27,28 After differentiation, 
the resulting SMCs were maintained in DMEM supplemented 
with 10% fetal bovine serum for at least 2 weeks before 
seeding onto UniFlex Culture Plates (FlexCell International 
Corporation). After 4 days, the SMCs were stretched for 48 
hours using a Cyclic Stress Unit (FX5000 Tension System, 
FlexCell International Corporation), using a cyclic sine wave (60 
cycles/min) and 10% elongation.
Gene Expression Analysis
Total RNA was isolated from aortic tissues (n=5 for control 
group and n=11 for MFS group), human aortic SMCs from 
TGF-β1 experiment (3 different donors with 6 technical repli-
cates for control, TGF-β1, and TGF-β1+ALKi groups), human 
aortic SMCs from siRNA experiment (3 different donors with 
14 technical replicates for both control siRNA and MFAP4 
siRNA group) and iPSC-SMCs using the miRNeasy Mini kit 
(Qiagen) as described previously.29 Briefly, 700 µL of QIAzol 
reagent was added to samples. A homogenization step in a 
Precellys 24-Dual homogenizer (Peqlab) using Lysing Matrix 
D ceramic beads (MP Biomedicals) was performed for tissues 
only. After a brief incubation at room temperature, 140 µL of 
chloroform was added, and the solution was mixed vigorously. 
The samples were then centrifuged at 16000g for 15 minutes 
at 4°C. The aqueous phase was carefully transferred to a new 
tube and mixed with 1.5 volumes of 100% ethanol. The sam-
ples were then applied directly to columns and washed accord-
ing to the manufacturer’s instructions. Total RNA was eluted 
in 25 µL of nuclease-free H2O. RNA was reverse-transcribed 
into cDNA using the High Capacity Reverse Transcriptase kit 
(Life Technologies). Quantitative polymerase chain reaction 
(qPCR) was performed using Taqman Assays to assess the 
gene expression levels with GAPDH as a normalization control.
For experiments concerning TGF-β1 stimulation of mouse 
aortic SMCs, RNA was isolated from SMCs with the Aurumn 
total RNA mini kit (BioRad) according to the manufacturer’s 
instructions. cDNA synthesis was performed with the iScript 
cDNA synthesis kit (BioRad). Specific primers were designed 
using Primer3 to analyze MFAP4 gene expression. The 60S 
acidic ribosomal protein P0 (Rplp0) gene was used for nor-
malization. Quantitative real-time PCR was performed on a 
LightCycler 480 system (Roche) using the SensiFAST SYBR 
No-ROX Kit (Bioline). All primers used for qPCR analysis 
are listed in Major Resources Tables in the online-only Data 
Supplement.
Histological Analysis and 
Immunohistochemistry
Alcian blue staining was performed in aortic tissues from 
patients with MFS (n=27) and controls (n=7) to visualize acidic 
polysaccharide accumulation, such as glycosaminoglycans 
and quantified (corrected for medial area) with QWin software 
(version 3.0, Leica Microsystem). Nuclear Fast red was used 
as counterstain for nuclei. Immunohistochemistry was per-
formed on 7 µm thick formalin-fixed paraffin embedded aor-
tic tissue sections from patients with MFS. Sections were first 
deparaffinized in xylene followed by rehydration. To quench 
the endogenous peroxidases, sections were treated with 2% 
hydrogen peroxide for 20 minutes, followed by a 30 minutes 
incubation with 10% normal goat serum and 1% BSA diluted 
in Tris-buffered saline to block nonspecific binding. The sec-
tions were then incubated overnight at 4°C with a polyclonal 
rabbit anti-MFAP4 antibody (Abcam, ab80319) diluted 1:500 
in Tris-buffered saline. Control sections were treated with nor-
mal rabbit IgG. The following day the slides were incubated 
for 30 minutes with an horseradish peroxidase-conjugated 
anti-rabbit immunoglobulin polymer (Immunologic) diluted 1:1 
with Tris-buffered saline followed by development with bright 
3,3′-Diaminobenzidine (Immunologic). The sections were coun-
terstained with Gill’s hematoxylin and mounted with Pertex.
MFAP4 Quantification in Plasma Samples From 
Patients With MFS
For the analysis of plasma protein levels of MFAP4, we used the 
same samples as described earlier (n=96).21 A human MFAP4 
ELISA kit (Elabscience, E-EL-H0581) was used to determine 
MFAP4 protein levels in plasma following the manufacturer’s 
instructions. Briefly, plasma samples from patients with MFS 
were diluted 1:50 with the standard and sample diluent pro-
vided. The samples were incubated for 90 minutes at 37°C in 
the provided wells coated with anti-MFAP4 antibody. Second, 
the samples were removed followed by a 1-hour incubation at 
37°C with the anti-MFAP4 biotinylated detection antibody. After 
washing, a 30 minutes incubation with an horseradish peroxi-
dase conjugate was followed by another washing step. Last, 
an horseradish peroxidase substrate was added for 5 minutes 
with subsequent addition of the stop solution. Optical density 
was measured at a wavelength of 450 nm with the ELx808 
ultra microplate reader (BioTek Instruments, Inc, Winooski, VT).
Ultrasonic and MRI Measurements of the Aorta
In the COMPARE patients, the aortic root diameter was mea-
sured at time of inclusion and during follow-up yearly by echo-
cardiography. The aortic growth rate (mm/y) was determined 
after 38 months of follow-up, by subtracting the root diameter 
at baseline from the most recent diameter, dividing this by the 
COMPARE follow-up period in years. Occurrence of events, 
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such as prophylactic aortic surgery or aortic dissection, were 
recorded during the follow-up of 68 months. Aortic distensi-
bility at 4 levels throughout the aorta was calculated: (1) the 
ascending aorta, (2) the descending thoracic aorta at the level 
of the bifurcation of the pulmonary artery, (3) the descending 
aorta at the level of the diaphragm, and (4) the abdominal aorta 
just above the bifurcation. Measurements were performed by a 
single analyst using cine magnetic resonance images, as previ-
ously described.5,21,30
Statistical Analysis
Continuous data are presented as mean with SD or median 
with range, as described in the figure legends. Categorical vari-
ables were summarized using proportions.
The quantities of the proteins/peptides were scaled using 
log2 transformation. The data sets were further filtered to keep 
only measurements with <30% missing values or with >90% 
missing values one of the examined conditions and <10% for 
the rest of the conditions. In the latter case, missing values of 
the condition which presented >90% of missing values were 
imputed with zeros. All remaining missing values were imputed 
with KNN-Impute method with k equal to the minimum among 
20 and the sample size of the phenotype with the fewest 
samples.
Before performing statistical comparison, we performed the 
Shapiro-Wilk normality test to check whether the relative quan-
tities were normally distributed.
For continuous variables with a normal distribution, differ-
ences between groups were analyzed with a Student t test. 
When the data were not normally distributed, nonparamet-
ric methods were used. In specific, for paired comparisons, 
the Wilcoxon signed-rank test and Mann-Whitney U test for 
unpaired comparisons were used. P values were adjusted using 
the Benjamini-Hochberg method, and a threshold of 0.05 was 
used for the adjusted P values to infer statistically significant 
changes.
Differences in categorical variables were analyzed with a 
χ2 or Fisher Exact test. The Kaplan-Meier analysis was used 
for comparisons of event-free survival. Statistical analysis was 
performed using SPSS software (version 24.0, IBM) or Python 
(version 3.7.2) scripts. Graphs were created with Graphpad 
Prism software (version 7.04).
RESULTS
Glycoproteomics of the Aortic ECM in Patients 
With MFS
Enhanced glycoprotein levels in the aorta of patients with 
MFS were demonstrated by Alcian blue staining, com-
pared with aneurysmal patients without MFS (Figure 1A). 
For glycoproteomics, thoracic aortic aneurysm samples 
from patients with and without MFS (n=11 and n=6, 
respectively, Table I in the online-only Data Supplement) 
Figure 1. Glycoprotein content in aneurysms of patients with Marfan syndrome (MFS).  
A, Alcian blue staining of aortic tissue sections from patients with MFS (n=27) and controls (n=7). Stronger blue staining indicates buildup 
of glycoproteins as well as mucopolysaccharides. Scale bars are 5µm. *P<0.05 by Student t test. B, Glycoproteomics workflow showing the 
3-step extraction, enrichment and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of extracellular matrix (ECM)-derived 
glycopeptides from thoracic aortic aneurysm tissue of control (n=6) and MFS patients (n=11). ETD indicates electron transfer dissociation; and 
HCD, higher-energy collisional dissociation; and SDS, sodium dodecyl sulphate.
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were compared. The ECM was extracted using our 3-step 
extraction protocol. The glycopeptides in the GuHCl frac-
tion were enriched and analyzed by a glycoproteomic 
approach on an Orbitrap Elite MS (Figure 1B). After man-
ual validation of the identified glycopeptides, a total of 
215 unique spectra, corresponding to 35 different glyco-
proteins, were confirmed. A total of 141 glycoforms on 47 
glycosites were identified (Table III in the online-only Data 
Supplement). Among these, 119 unique spectra were 
deemed suitable for further quantitative analysis using 
their precursor peak area. In total, 38 N-linked glycopep-
tides from 8 ECM proteins were differentially expressed. 
The most significant differences between MFS and non-
MFS were observed for MFAP4, as well as for the 2 
large aggregating PGCA (proteoglycans aggrecan) and 
CSPG2 (versican; Figure 2A, Table IV in the online-only 
Data Supplement). MFAP4 has 2 N-glycosites at aspar-
agine (N) positions N87 and N137. Interestingly, only 5 
glycoforms were identified at N87 compared with 21 
glycoforms at N137. Compared with all other identified 
glycoproteins, MFAP4 exhibited the greatest number of 
unique glycoforms overall (Figure 2B).
Glycan Heterogeneity of MFAP4
Next, we focused on the glycoform diversity present at 
the 2 glycosites of MFAP4. Representative MS/MS 
spectra from glycopeptides derived from the N87 and 
N137 sites are provided (Figure I in the online-only Data 
Supplement). We discovered that glycopeptides corre-
sponding to both glycosites displayed significantly higher 
abundance in the aortic ECM of MFS patients compared 
to non-MFS controls (Figure 3A). Notably, glycans linked 
to N87 all belonged to the high-mannose class. Of these, 
glycopeptides consisting of 8 to 10 monosaccharides 
were increased in samples from patients with MFS while 
no significant changes were observed for glycopeptides 
with 6 or 7 monosaccharides (Figure 3B). More diverse 
glycans were attached to the N137 glycosite. Contrary to 
N87, only one out of 13 glycans was high-mannose, and 
the corresponding glycopeptide was increased in patients 
with MFS. All other glycans were of a hybrid/complex 
class, of which 11 corresponding glycopeptides were sig-
nificantly increased in patients with MFS (Figure 3C).
MFAP4 Gene Expression in Patients With MFS
To complement the proteomics data, we determined the 
corresponding levels of gene expression for a select 
panel of ECM proteins. From a subset of the same aortic 
specimens used for glycoproteomics analysis (n=5 for 
control group and n=11 for MFS group), the mRNA lev-
els of 55 ECM protein genes were quantified by qPCR. 
The mRNA levels of several elastin fiber-related proteins 
were significantly higher in MFS patients compared with 
controls, including fibulin-5 (FBLN5), latent-transform-
ing growth factor-β-binding protein 1 (LTBP1), and 4 
(LTBP4) as well as MFAP4 (Figure 4A, Table V in the 
online-only Data Supplement).
MFAP4 in Patients With BAV
The presence of a BAV is a predisposing factor for the 
development of thoracic aortic aneurysms.31 To explore 
Figure 2. Glycoproteomic analysis of the aortic extracellular matrix (ECM) in aneurysms of patients with Marfan syndrome 
(MFS).  
A, Volcano plot showing the difference in abundance of glycopeptides derived from ECM proteins in thoracic aneurysms of MFS vs control 
patients. Versican (CSPG2), MFAP4 (microfibril-associated glycoprotein 4), and PGCA (proteoglycans aggrecan) have been highlighted 
with their accompanying glycosylation sites. Different data points for the same color represent alternative glycans at the same glycosylation 
site. Mann-Whitney U tests were used with multiple testing adjustment. Thresholds for significance are indicated by dotted lines (P<0.05 
and fold change <0.5 or >2). B, All identified glycoproteins are plotted according to their number of unique glycosites and number of unique 
glycoforms. MFAP4 possesses the highest number of unique glycoforms.
D
ow
nloaded from
 http://ahajournals.org by on July 31, 2019
OR
IG
IN
AL
 R
ES
EA
RC
H 
- V
B
Yin et al Glycoproteomics of Marfan Syndrome
September 2019 Arterioscler Thromb Vasc Biol. 2019;39:00–00. DOI: 10.1161/ATVBAHA.118.3121758
whether MFAP4 may be upregulated in early stages of 
this disease, we obtained aortic specimens from patients 
with BAV not presenting with aortic aneurysms (Table II 
in the online-only Data Supplement). Using proteomics, 
we compared the ECM of the convex and concave area 
within the same nonaneurysmal aortas (n=8). The con-
vex area of the ascending aorta is more prone to aneu-
rysmal development, most likely because of shear stress 
exposure, which is altered in BAV patients compared 
with individuals with TAV.32 Interestingly, we found that 
although no aortic aneurysms were present, the abun-
dance of MFAP4 protein was higher in the convex area 
when analyzed by LC-MS/MS. Notably, the increase in 
MFAP4 was accompanied by a rise in FBN1 (Figure 4B, 
Table VI in the online-only Data Supplement). MFAP4 
and FBN1 were validated by a targeted multiple reac-
tion monitoring method in GuHCl fraction of concave and 
convex samples of aortas from both nonaneurysmal BAV 
patients and nonaneurysmal TAV patients (n=7). These 2 
proteins were significantly increased (MFAP4: 1.54-fold 
increase, P=0.025; FBN1: 1.67-fold increase, P=0.029) 
in the convex area of BAV patients compared to the 
concave area, but this was not the case in TAV patients 
(MFAP4: 1.35-fold increase, P=0.231; FBN1: 2.19-fold 
increase, P=0.075; Figure II and Table VII in the online-
only Data Supplement).
MFAP4, Proteoglycans, and ADAMTS Proteases 
in MFS
Using an N-terminal antibody for MFAP4, we confirmed 
an increase in MFAP4 levels in the NaCl fraction (Fig-
ure 4C) but not in the GuHCl fraction (Figure 4D) of 
MFS aortic tissue. Alongside MFAP4, the large aggre-
gating CSPG2 and PGCA were increased in the gly-
copeptide analysis without corresponding changes in 
gene expression. Large aggregating proteoglycans are 
cleaved by members of the ADAMTS (a disintegrin and 
metalloproteinase with thrombospondin motifs) fam-
ily. Two anti-neoepitope antibodies were used to detect 
ADAMTS-specific cleavage of aggrecan and versican 
in MFS: the aggrecan neoepitope antibody detects the 
neoepitope sequence NITEGE, generated by ADAMTS-
cleavage at the position Glu373-Ala374 in the core 
Figure 3. Increased MFAP4 (microfibril-associated glycoprotein 4) glycopeptides in patients with Marfan syndrome (MFS). 
A, Quantification of the overall glycopeptide abundance in the 2 MFAP4 glycosites between MFS and control groups. B, Quantification of 
glycopeptides with different high-mannose glycans on N87 of MFAP4. C, Quantification of glycopeptides with different glycans on N137. Box 
and whisker plots represent the second and third quartiles and error bars expand from the 10th to the 90th percentiles. Circled data points 
along the x-axis represent no detection (n=6 for control and n=11 for MFS, with duplicate liquid chromatography-tandem mass spectrometry 
[LC-MS/MS] runs for each sample). dHex indicates L-Fucose; Hex, Hexose; HexNAc, N-Acetyl-Hexose; and NeuAc, N-Acetylneuraminic acid. 
*P<0.05, **P<0.01 by Mann-Whitney U test with multiple testing adjustment using Benjamini-Hochberg method.
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protein; the versican neoepitope antibody detects the 
neoepitope sequence DPEAAE, generated by ADAMTS-
cleavage at the position Glu441-Ala442 of the protein 
core of versican isoform V1.33 Detection of both neoepi-
topes was higher in the GuHCl fraction of patients with 
MFS compared with control but only versican reached 
statistical significance. Interestingly, levels of TGF-β1 
remained unaltered between MFS and control patients 
(Figure III in the online-only Data Supplement).
Regulation of MFAP4 Expression
TGF-β1 has been implicated in the pathophysiology of 
aortic aneurysms in patients with and without MFS, via 
both direct genetic mutations in the TGF-β pathway 
(Loeys-Dietz Syndrome) and as a consequence of FBN1 
mutations (MFS) leading to dysregulated TGF-β1 levels 
in the pericellular environment and excessive TGF-β1 
signaling through ALK receptors. In human and murine 
aortic SMCs, administration of TGF-β1 upregulated 
MFAP4 gene expression. This effect was fully reversed 
by the presence of an ALK receptor inhibitor (Figure 5A 
and 5B, Table VIII in the online-only Data Supplement). 
Therefore, TGF-β1 may function as a transcriptional 
regulator of MFAP4 in arterial SMCs and contribute to 
MFAP4 regulation during aortopathy.
Silencing of MFAP4 in Human Aortic SMCs
To investigate the functional consequences of altera-
tions in MFAP4 expression, we used a gene silencing 
approach to inhibit MFAP4 translation in cultured human 
aortic SMCs. Efficient knockdown of MFAP4 (Log2 
fold change =−4.34 compared with control, P=0.004) 
resulted in increased expression of elastin (ELN, Log2 
fold change =2.35, P=0.004) and reduced expression 
of FBN1 (Log2 fold change =−0.50, P=0.005). Interest-
ingly, silencing of MFAP4 also significantly attenuated 
the expression of versican (VCAN, Log2 fold change 
=−0.50, P=0.007), whereas aggrecan (ACAN) expres-
sion was variable between different donors (Figure 5C, 
Figure IV and Table IX in the online-only Data Supple-
ment). We have recently highlighted the importance of 
aggrecan and the ADAMTS family in stent-induced vas-
cular injury.34 Moreover, ADAMTS family members have 
been implicated in murine thoracic aortic aneurysm for-
mation.24,35 To further investigate whether MFAP4 may 
be linked to ADAMTS enzymes, we tested the expres-
sion levels of ADAMTS-1 and -4. While ADAMTS-1 
(Log2 fold change =−0.80, P=0.004) was significantly 
decreased after MFAP4 knockdown, ADAMTS-4 (Log2 
fold change =0.54, P=0.055) appeared to be margin-
ally increased (Figure 5C). Unlike ADAMTS proteases, 
Figure 4. MFAP4 (microfibril-associated glycoprotein 4) expression is upregulated in Marfan syndrome (MFS).  
A, Volcano plot showing the differences in gene expression of selected extracellular matrix (ECM) proteins between aneurysmal thoracic aortic 
tissue from patients with MFS (n=10) and controls (n=5). P values were calculated using Mann-Whitney U test. B, Volcano plot showing the 
ECM protein differences between concave and convex area of the same thoracic aorta from nonaneurysmal BAV patients (n=8). P values were 
calculated using Wilcoxon signed-rank test. Immunoblotting for MFAP4 in the NaCl (C) and guanidine hydrochloride (GuHCl) samples (D) 
between aneurysmal thoracic aortic tissue from patients with MFS (n=10) and controls (n=5). Please note the control sample in lane 1 with 
high MFAP4 in the NaCl fraction is from a patient with a TGFBR1 (transforming growth factor β receptor type 1) mutation. FBN1 indicates 
fibrillin-1. Student t test: *P<0.05.
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the expression of 3 MMPs (matrix metalloproteinases), 
namely MMP2 (collagenase), MMP9 (collagenase), and 
MMP12 (elastase), did not show significant changes in 
response to MFAP4 inhibition (Table IX in the online-only 
Data Supplement).
Induced Pluripotent Stem Cells-Derived SMCs
It is worth noting that apart from MFAP4 other elas-
tic fiber-interacting proteins were increased as well in 
gene expression data from MFS aortas, such as FBLN5, 
LTBPs, and MFGE8 (Figure 4A). To further investigate the 
Figure 5. Changes of MFAP4 (microfibril-associated glycoprotein 4) in relation to TGF-β1 (transforming growth factor β receptor 
type 1), ELN (elastin), and FBN1 (fibrillin-1).  
MFAP4 gene expression was quantified in human (A) and murine (B) aortic smooth muscle cell (SMCs) after incubation with TGF-β1 in the 
absence or presence of an ALKi (activin-like kinase 4,5,7 inhibitor). Data points are individual replicates with horizontal bars representing the 
average. The dashed line represents the control (no TGF-β1, no ALKi) average, which was set to 1. P values were calculated using Student 
t test. *P<0.05, ***P<0.001 vs TGF-β1 group; #P<0.05, ###P<0.001 vs Control group. C, Silencing of MFAP4 by siRNA in human aortic 
SMCs (from 3 different donors) resulted in mRNA changes of various extracellular matrix (ECM) proteins and members of the ADAMTS 
(a disintegrin and metalloproteinase with thrombospondin motifs) family. Gene expression was normalized to control group (dotted line). 
Nonparametric paired test was performed and adjusted P value was calculated. **P<0.01. D, SMCs were differentiated from iPSCs (induced 
pluripotent stem cell) derived from a Marfan syndrome (MFS) patient and the FBN1 mutation was corrected by CRISPR/Cas9 (Corr). Cells 
were cultured under unstretched (US) or stretched (S) conditions. Gene expression was normalized to corrected unstretched (Corr US) group 
(dotted line). In the absence of elastin expression, no changes in MFAP4 were observed. Unpaired Student t test was performed and adjusted 
P value was calculated. *P<0.05, **P<0.01 compared to Corr US group; ##P<0.01 compared to Corr S group.
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functional links between FBN1, ELN, and MFAP4, skin 
fibroblasts of a patient with MFS were reprogrammed 
into iPSCs. The FBN1 gene mutation was corrected 
using CRISPR-Cas9 to provide an isogenic control.26 
Both the FBN1-mutant iPSCs and FBN1-corrected 
iPSCs were further differentiated into neural crest vas-
cular SMCs.26 Gene expression was assessed by qPCR 
under static and stretch conditions. FBN1 expression 
was higher in the SMCs from the patients with MFS than 
in the corrected isogenic control under both conditions 
(P<0.01 for both comparison). When elastin expression 
was undetectable in these iPSC-derived SMCs (Ct >35 
cycles), expression levels of MFAP4 were unchanged 
(Figure 5D).
Figure 6. Plasma levels of MFAP4 (microfibril-associated glycoprotein 4) predict the occurrence of type B dissections.  
A, Aortic tissues from patients with Marfan syndrome (MFS) were stained for MFAP4 (red-brown) with hematoxylin (blue) nuclear 
counterstaining. MFAP4 is localized throughout the vessel wall with prominent staining of the internal elastic lamina (arrow), the adventitia and 
the medial layer. Scale bars are 100 µm. B, The distensibility measurements in patients with MFS are shown at the ascending (level 1; n=54 
vs n=25), proximal descending (level 2; n=53 vs n=25), distal descending (level 3; n=53 vs n=25) thoracic aorta and abdominal aorta (level 
4; n=46 vs n=24), according to low (bottom 2 tertiles) vs high (upper tertile) plasma MFAP4 concentrations. Survival curve showing the aortic 
surgery incidence (C) and aortic dissection incidence (D) in the 68-mo follow-up period in MFS patients with low (bottom 2 tertiles; n=64) vs 
high (upper tertile; n=32) plasma MFAP4 levels. High plasma MFAP4 levels were associated with a high dissection incidence. The Kaplan-
Meier analysis was used for comparisons of event-free survival.
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Localization of MFAP4
To determine the localization of MFAP4, we performed 
immunostaining of histological sections from aortas of 
patients with MFS. MFAP4 colocalized with the internal 
elastic lamina in the aortic wall and in the adventitia at 
the external elastic lamina and possibly also with colla-
gen fibrils (Figure 6A).
MFAP4 Plasma Levels Associate With Aortic 
Distensibility and Dissection in MFS
In addition to its expression in the aortic ECM, MFAP4 
was detectable in plasma obtained from a subpopula-
tion of patients with MFS from the COMPARE trial 
(n=96).21 To determine whether plasma MFAP4 associ-
ates with aortic events, the 96 patients with MFS were 
subdivided into 3 equal tertiles (lower, middle, and upper 
tertile) based on their MFAP4 protein levels. Patient 
demographics of each tertile are summarized in Table X 
in the online-only Data Supplement. No significant dif-
ferences were observed for sex, age, usage of blood 
pressure lowering agents at time of inclusion or the per-
centage of patients who have undergone prophylactic 
aortic surgery before or during follow-up. Twenty aortic 
root replacements and 5 type B dissections (ie, affect-
ing the descending thoracic aorta) occurred during the 
68 months follow-up period. Interestingly, all type B dis-
sections occurred in patients from the upper tertile (high 
plasma MFAP4). Because there was no significant differ-
ence in plasma MFAP4 levels between patients with or 
without previous aortic root replacement, MFAP4 seems 
to be independent from this well-known risk factor for 
type B dissections. Moreover, high plasma MFAP4 levels 
or type B dissections were not related to any of the blood 
pressure lowering drugs used.
To study local aorta characteristics, the aortic disten-
sibility, which is a measure for aortic wall elasticity, was 
measured at 4 locations: the ascending aorta (level 1, 
n=79), the descending thoracic aorta at the level of the 
bifurcation of the pulmonary artery (level 2, n=78), the 
descending aorta at the level of the diaphragm (level 3, 
n=78), and the abdominal aorta just above the bifurca-
tion (level 4, n=70). Lower distensibility was observed at 
the proximal (level 2, P=0.053) and the distal (level 3, 
P=0.003) descending thoracic aorta in patients with high 
plasma MFAP4 levels (the upper tertile; Figure 6B, Table 
X in the online-only Data Supplement). These are the 
2 locations where type B dissections occur in patients 
with MFS. While in our previous study high plasma TGF-
β1 correlated to the incidence of prophylactic aortic root 
surgery during follow-up (as surrogate for aortic root 
growth),21 high plasma MFAP4 was not associated with 
prophylactic aortic root surgery (P=0.74, Figure 6C). 
However, it was associated with a reduction in dissec-
tion-free survival in this cohort (P=0.025, Figure 6D).
DISCUSSION
ECM degradation and remodeling are hallmarks of aortic 
aneurysm pathology.36 Previously, we established an extrac-
tion methodology for ECM proteins and performed the first 
ECM proteomic comparison between control human aortas 
and abdominal aortic aneurysms.18,36 To further study the 
involvement of ECM proteins in aortic aneurysm formation, 
we provide a glycoproteomics characterization of MFS, a 
condition strongly associated with premature aortopathy. 
We provide evidence for altered glycosylation of MFAP4, 
a protein involved in elastic fiber assembly. Thus, changes 
in ECM proteins in MFS are not confined to abundance 
only, but involve PTMs, which have been far less studied. 
To substantiate the clinical relevance of MFAP4 in patients 
with MFS, we demonstrate that increased plasma levels of 
MFAP4 associate with reduced aortic distensibility and a 
higher incidence of type B dissection.
Glycosylation of MFAP4 in the Human Aorta
Glycosylation is one of the most prominent and complex 
PTMs. Glycans have the ability to alter the mass, charge, 
and electrophoretic properties of proteins, influencing pro-
tein folding, stability, activity, distribution, targeting, and rec-
ognition.37 Moreover, gain-in-glycosylation mutations have 
been shown to comprise a significant number of pathogenic 
mutations, presenting in pathologies such as MFS.38 Sev-
eral glycopeptides displayed altered levels in patients with 
MFS, the highest number of which were glycopeptides from 
MFAP4. MFAP4 contains 2 N-glycosylation sites and evi-
dence for MFAP4 glycosylation was previously established 
by N-terminal sequencing of the recombinant glycoprotein.39 
The functional impact of MFAP glycosylation changes has 
been suggested previously, since this may result in a more 
negatively charged glycoprotein, which confers a stronger 
electrostatic affinity to positively charged proteins, such as 
tropoelastin.40 A greater negative charge in MFAP4 could 
be achieved on accumulation of sialic acid (NeuAc), the only 
glycan-building monomer bearing a net negative charge.41 
Moreover, the presence of sialic acid is restricted to gly-
cans attached to the N137 position of MFAP4, and the 
majority of corresponding glycopeptides were increased in 
the aortic ECM of MFS patients. Therefore, certain glyco-
forms might be favored at specific glycosylation sites, which 
could underlie a compensatory response that enhances the 
interaction of MFAP4 with elastin fibers during aneurysmal 
development to strengthen the integrity of the vessel wall. 
This concept of adaptive regulation in response to changes 
in elastic fiber content has previously been observed in a 
proteomic analysis of aortic aneurysms.42
MFAP4 in Elastic Fibre Composition
Elastic fiber breakage is a key characteristic of aortopa-
thy, as which occurs in MFS.43 Underlying elastin micro-
fibrils contain FBN1, LTBPs, fibulins, MFAPs, and other 
D
ow
nloaded from
 http://ahajournals.org by on July 31, 2019
ORIGINAL RESEARCH - VB
Yin et al Glycoproteomics of Marfan Syndrome
Arterioscler Thromb Vasc Biol. 2019;39:00–00. DOI: 10.1161/ATVBAHA.118.312175 September 2019 13
MAGPs (microfibril-associated glycoproteins).44 MFAP4 
mainly localizes at sites rich in elastic fibers and is known 
to be involved in their assembly and maintenance.45 It 
is noteworthy that mRNA levels of MFAP4 are higher 
in MFS compared with control patients and also that 
mRNA levels of ELN were upregulated when MFAP4 
knockdown was performed in human aortic SMCs. Inter-
estingly, a 2-fold increase in MFAP4 abundance in the 
ascending aorta of patients with MFS has been previ-
ously reported using difference in-gel electrophoresis.46 
The coordinated expression with FBN1 may be expected, 
given that MFAP4 has been demonstrated to bind and 
colocalize with FBN1 to aid in elastin fiber formation.45 
However, correction of the FBN1 mutation in iPSC-
derived vascular SMCs had no direct effect on MFAP4 
levels, as these SMCs produced little elastin in culture. 
In some iPSC-derived SMCs with detectable elastin 
expression (Ct <35 cycles), however, a correspond-
ing increase in MFAP4 expression was observed (data 
not shown). Thus, the rise in MFAP4 is a compensatory 
response to the abnormal elastin formation in patients 
with MFS rather than a direct consequence of the FBN1 
mutation. Apart from MFAP4, compensatory changes 
were also observed for other elastin accessory proteins 
at the predilection site of nonaneurysmal aortas from 
BAV patients. While these early compensatory mecha-
nisms may transiently improve interactions between fiber 
components, they might constitute defective long-term 
remodeling of the vascular ECM. It is noteworthy that 
MFAP4 has been shown to promote SMC proliferation 
and migration during vascular injury,45,47 supporting the 
concept that ECM remodeling also provides direct sig-
nals to cells within the ECM.
MFAP4 and TGF-β1 Signaling
It has been suggested that mutant FBN1 expressed in 
the ECM leads to excessive TGF-β signaling, thereby 
coordinating the pathophysiological sequelae of MFS.48 
This hypothesis has recently been challenged by clini-
cal trials showing no superiority of losartan, an inhibitor 
of TGF-β production, over or alongside conventional β-
blocker therapy.6–8 In arterial SMCs from humans and 
mice, TGF-β1 was a potent inducer of MFAP4 expression. 
However, plasma TGF-β1 and plasma MFAP4 each pre-
dicted different aortic events in patients with MFS, sug-
gesting that there will be additional inducers of MFAP4 to 
be discovered. In contrast to other studies,49–51 we failed 
to observe a significant change in TGF-β1 protein levels 
in the aortic ECM of patients with MFS versus controls.
MFAP4 and Proteoglycan Turnover
Changes in the large aggregating proteoglycans versi-
can and aggrecan at the glycopeptide level accompanied 
those observed for MFAP4 in patients with MFS. Our 
laboratory has previously highlighted the role of ADAMTS 
proteases in the proteolysis of aggrecan and versican in 
the vasculature.34 In patients with MFS, we observed an 
increase in the ADAMTS-mediated cleavage product of 
versican. This may reflect a buildup of proteoglycan sub-
strate, which has been shown to occur in patients with 
thoracic aortic aneurysm or dissection, including those 
with MFS.52 Notably, our experiments showed for the 
first time that a reduction of MFAP4 in SMCs leads to a 
parallel reduction in the expression of versican, as well 
as several different changes in the ADAMTS enzyme 
family. Changes in ECM may act as signaling mecha-
nisms affecting ADAMTS expression and activity on the 
large aggregating proteoglycans. Reduced expression 
of ADAMTS-1 in mice and humans has previously been 
associated with MFS-related aortopathy,35 but our most 
recent data point towards a greater role for ADAMTS-5, 
at least in mice.25 The contribution of proteoglycans 
and their remodeling to the pathology of MFS in aortas 
will require further investigation, especially since muta-
tions in ADAMTS family members were found to phe-
nocopy genetic disorders caused by mutations affecting 
FBN1.53,54
MFAP4 as Plasma Biomarker for Vascular 
Remodeling
In the present study, we demonstrated that MFAP4 is 
abundant in the aortic vessel wall of patients with MFS 
and that type B dissections occurred during follow-up 
in the patients with high plasma MFAP4. Higher plasma 
MFAP4 levels also associated with a lower descending 
thoracic aorta distensibility. The association of aortic dis-
tensibility of the thoracic descending aorta and type B 
dissections has been made previously.5 It is especially 
interesting that MFAP4 is not associated with prophy-
lactic aortic root surgery, which is a known risk factor 
for type B dissections. Therefore, plasma TGF-β1 levels 
associate with aortic root growth and, therefore, may pre-
dict prophylactic aortic root surgery to prevent type A dis-
sections,21 whereas plasma MFAP4 levels seem related 
to reduced distensibility of the descending aorta and pre-
dict the probability of a type B dissection. Although these 
findings await confirmation in larger cohorts, MFAP4 is 
an interesting candidate biomarker to identify patients 
with MFS at higher risk for type B dissection, who could 
be monitored more closely.
Conclusions
The majority of patients with MFS have a greater pro-
pensity to experience thoracic aortic aneurysms and 
dissections. Until now, no in-depth glycoproteomics 
characterization of the vascular ECM in patients with 
MFS has been performed. Our glycoproteomics analysis 
revealed that MFAP4 glycosylation is enhanced in MFS 
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patients with aortic aneurysms compared with aneu-
rysms in patients without MFS. In addition to its altered 
glycosylation profile in MFS, knockdown of MFAP4 
expression in aortic SMCs also had a profound impact on 
the expression of key ECM components such as elastin 
and FBN1 as well as ADAMTS proteases and versican. 
Taken together, our findings reinforce the notion of an 
interplay between elastic fiber-associated proteins and 
large aggregating proteoglycans during aortic pathol-
ogy.55 ECM remodeling is a hallmark of many vascular 
pathologies, and the application of glycoproteomics to 
the analysis of clinical samples provides insights into the 
changes in essential ECM components which occur dur-
ing disease, which may lead to the discovery of novel 
biomarkers and potential therapeutic interventions.
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